MetaCap

Medicinova (MNOV) vs PMV Pharmaceuticals (PMVP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Medicinova (MNOV) has outperformed PMV Pharmaceuticals (PMVP) over the past year, losing 8.4% versus a loss of 33.6%. Over five years, MNOV leads with a -59.3% price change compared with -96.2% for PMVP. Medicinova is the larger company by market cap ($67.1 million vs $66.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MNOV-8.39%PMVP-33.64%
+150%+54%-42%
Nov 21, 20251 yearNov 20, 2026
MNOV-59.19%PMVP-96.51%
+8%-47%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MNOV versus PMVP key metrics
MetricMNOVPMVP
Share price$1.31$0.876
Market cap$67.11M$66.17M
1-day change+3.15%-33.13%
YTD return0.00%-29.92%
1-year return-8.39%-33.64%
5-year return-59.32%-96.22%
EPS (TTM)$-0.21$-1.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$409.66K—
Net income (latest FY)$-12.00M$-77.74M
Operating margin-3242.47%—
Net margin-2928.78%—
52-week high$3.90$1.91
52-week low$1.22$0.66
Distance from 52-week high-66.41%-54.14%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+529.77%+356.62%
Average volume334.96K787.50K
Shares outstanding51.23M75.53M
Employees654
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MNOV has outperformed PMVP by 25.2 percentage points over the past year.

About Medicinova

MNOV stock →

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About PMV Pharmaceuticals

PMVP stock →

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees

MNOV vs PMVP FAQ

Which is bigger, Medicinova or PMV Pharmaceuticals?

Medicinova (MNOV) is larger, with a market capitalization of $67.11M compared with $66.17M for PMV Pharmaceuticals (PMVP).

Which stock has performed better over the past year, MNOV or PMVP?

MNOV returned -8.39% over the past 12 months, compared with -33.64% for PMVP (price return, excluding dividends). Past performance does not predict future results.

Are Medicinova and PMV Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons